H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Tyme Technologies (TYME – Research Report) today and set a price target of $9.50. The company’s shares closed last Monday at $1.75.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -3.6% and a 37.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Zomedica Pharmaceuticals, and ThermoGenesis Holdings.
Tyme Technologies has an analyst consensus of Strong Buy, with a price target consensus of $8.50.
Based on Tyme Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.13 million. In comparison, last year the company had a GAAP net loss of $8.05 million.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TYME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell’s protein synthesis.